CXCL10 and bladder transitional cell carcinoma: We found that in multiple immune therapy cohorts, such as Imvigor 210, an immune therapy cohort for BLCA, high expression of CXCL10 indicates better immune therapy outcomes, including the popular immune checkpoint inhibitor therapy and adoptive cell therapy.